Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ANTIPARASITIC COULD REDUCE CHANCE OF COVID DEATHS UP TO 75%

Ivermectin, an off-patent antiparasitic drug, has shown promise in the treatment of patients with moderate to severe cases of COVID-19, and in some studies have reduced the chance of death by 75 percent, according to a report last week in the Financial Times.
The report said the drug is usually used in the treatment of parasitic infections.
“It’s a generic drug used all over the world,” Andrew Hill, one of the researchers at the University of Liverpool, told the paper. “It costs $0.12 to make the drug substance. The drug costs $3 in India, $960 in the US.”
Harold told the paper the drug seems to make people less infectious when they come down with the virus. He told the paper that vaccination is “central to the response to the pandemic. But this might help reduce infection rates by making people less infectious and it might reduce death rates by treating the viral infection.”
Researchers admit that more studies need to be conducted, and they published their findings in EClinicalMedicine, a clinical journal published by The Lancet. The antiparasitic drug reportedly reduces the replication of the virus inside humans.
“Although our study is small and it is too early to draw conclusions, the trends observed in viral loads, symptom duration, and antibody levels are encouraging and warrant further exploration in larger clinical trials with a higher diversity of patients,” said Carlos Chaccour, Research Professor at Barcelona Institute for Global Health (ISGlobal). 
TREND FORECAST: Alternatives to fighting the coronavirus are barely reported in the mainstream media and most often readily dismissed. 
As we have pointed out since the COVID War began, rarely, if ever, has the media, politicians, and the anointed “health experts” recommended that people eat healthily, build their immune systems, and consider natural healing remedies. 

Comments are closed.